Quote | JanOne Inc. (NYSE:JAN)
Last: | $ |
---|---|
Change Percent: | 0.17% |
Open: | $3.49 |
Close: | $3.5161 |
High: | $3.6999 |
Low: | $3.43 |
Volume: | 57,158 |
Last Trade Date Time: | 02/12/2020 04:43:27 pm |
News | JanOne Inc. (NYSE:JAN)
2024-04-18 13:33:02 ET More on JanOne Financial information for JanOne Read the full article on Seeking Alpha For further details see: JanOne files $100M mixed securities shelf
2024-04-16 13:00:24 ET More on Industrial Select Sector SPDR ETF Eclipsed: Energy, Grids, Infrastructure, And Innovation XLI ETF: Seek More Aero And Defense Exposure XLI: Great Set Of Blue Chip Stocks, Sending Mixed Messages Boeing weighs on large-cap industr...
Message Board Posts | JanOne Inc. (NYSE:JAN)
Subject | By | Source | When |
---|---|---|---|
$JAN we just got $24M so let's do | wickerman | investorshub | 03/23/2023 2:52:31 PM |
Huge volume today | Golden Cross | investorshub | 03/16/2023 11:09:32 PM |
Jan headed for NASDAQ delisting | againstallodds | investorshub | 01/18/2023 11:08:40 PM |
It isn't just Polte, the last I had | Principian | investorshub | 10/08/2022 7:06:45 PM |
if you though they had nothing before. Just | EXGeotraqEmp1 | investorshub | 09/27/2022 1:47:32 PM |
News, Short Squeeze, Breakout and More Instantly...
JanOne Inc. Company Name:
JAN Stock Symbol:
NYSE Market:
Shares of JanOne Inc. (NASDAQ: JAN) traded at a new 52-week high today and are currently trading at $3.29. So far today, approximately 102.47k shares have been exchanged, as compared to an average 30-day volume of 135.62k shares. JanOne Inc., a clinical-stage biopharmaceutical company, focuse...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...